BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Neurology

Corcept Therapeutics Submits NDA for Relacorilant to FDA for Cushing’s Syndrome Treatment

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocr...

January 01, 2025 | News

GNT Pharma Announces Promising Nelonemdaz Results, Initiates Global Phase 3 Stroke Trials

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Mult...

December 12, 2024 | News

Actinogen Expands Alzheimer’s Trial Across Australia and US, Eyes Interim Results in 2025

Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell X...

December 10, 2024 | News

SNUBH, CurePSP, and GemVax Unite to Establish Korea’s First International PSP Research and Treatment Center

MOU Signed Among SNUBH-CurePSP-GemVax for the Establishment of International PSP Research and Treatment Center Tackling Global Challenges in an Aging Er...

December 10, 2024 | News

Alamar Biosciences Expands to APAC with ARGO™ HT System Installation at HKCeND

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in th...

December 09, 2024 | News

ShiraTronics Launches Pivotal RELIEV-CM2 Trial with First Neuromodulation Implants for Chronic Migraine in the U.S. and Australia

First Implants of Innovative Device Completed in the United States and Australia ShiraTronics, a clinical-stage innovator in neuromodulatio...

December 04, 2024 | News

Serina Therapeutics Secures $10 Million Equity Financing from JuvVentures to Advance Parkinson's Therapy

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, announced a $10 million equity fi...

December 03, 2024 | News

Eisai and Biogen Japan Partner with NCNP for APOE Genetic Testing in Alzheimer’s Research

Eisai Co., Ltd. and Biogen Japan Ltd. announced that Eisai has entered into a research collaboration agreement with the National Center of Neurology and Ps...

November 27, 2024 | News

HanAll Biopharma, Daewoong Pharmaceutical, and NurrOn Complete Phase 1 Study of HL192 (ATH-399A) for Parkinson’s Disease

HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. No serious treatment related adverse events were reported...

November 26, 2024 | News

ReviR Therapeutics Secures Kennedy’s Disease Association Grant to Advance Therapy for Rare Neuromuscular Disorder

ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a gro...

November 26, 2024 | News

Eisai Launches Rozebalamin® in Japan, Offering New Hope for ALS Patients

Eisai Co., Ltd. announced that the amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection25 mg” (mecobalamin) has ...

November 21, 2024 | News

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson's Biomarker Discovery

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration w...

November 20, 2024 | News

Lilly’s SGD$42 Million AI-Driven Digital Health Hub in Singapore Set to Transform Global Research in Cardio, Neuro, and Oncology

Lilly to drive next-generation AI powered digital health technology research in Singapore Lilly Digital ...

November 15, 2024 | News

Thermo Fisher’s Oncomine Dx Target Test Receives FDA Approval to Guide Treatment with Servier’s VORANIGO® for Grade 2 IDH-Mutant Glioma

Oncomine Dx Target Test to Identify Patients Eligible for Servier’s VORANIGO® (vorasidenib) tablet, the only FDA-approved treatment for Grade 2 I...

October 22, 2024 | News

Stay Connected